key: cord-0698224-3peafuz3
authors: Carbonell‐Sahuquillo, Silvia; Lázaro‐Carreño, María I.; Camacho, Jorge; Barrés‐Fernández, Ana; Albert, Eliseo; Torres, Ignacio; Bretón‐Martínez, José R.; Martínez‐Costa, Cecilia; Navarro, David
title: Evaluation of a rapid antigen detection test (Panbio™ COVID‐19 Ag Rapid Test Device) as a point‐of‐care diagnostic tool for COVID‐19 in a pediatric emergency department
date: 2021-07-27
journal: J Med Virol
DOI: 10.1002/jmv.27220
sha: 7b90b225aad39fd9ff736a2befaec5b12410df44
doc_id: 698224
cord_uid: 3peafuz3

We evaluated the Panbio™ COVID‐19 Ag Rapid Test Device as a point‐of‐care diagnostic tool for COVID‐19 in 357 patients at a pediatric emergency department. Thirty‐four patients tested positive by reverse transcription polymerase chain reaction, of which 24 were positive by the antigen assay. The sensitivity and specificity of the assay were 70.5% and 100%, respectively.

During the study period, 3522 patients attended, of whom 357 had suspected COVID-19 and were tested for the presence of SARS-CoV-2 in NP specimens (Table 1) . The most common manifestations in these latter patients were <24 h fever (75.0%), rhinorrhea, dry cough (44.8%), bronchospasms (21.9%), and diarrhea (17.9%). A total of 35 (9.8%) patients required hospital admission.

3.2 | Overall clinical performance of the RAD assay at the pediatric emergency department Of the 357 patients, 34 (9.5%) tested positive by RT-PCR, 24 (6.7%) of whom also had positive results by RAD. There were no RAD+/RT-PCR-cases, while both tests returned negative results in 323 patients (90.4%). Thus, the level of agreement between the results provided by the two tests was good (κ index, 0.81; 95% confidence interval [CI], 0.70-0.92). Accordingly, the overall sensitivity of RAD was 70.6% (95% CI, 52.2-84.9), while its specificity was 100% (95% CI, 98.9-100). Adjusted to the median prevalence of positive cases within the study period in our Department of Health (15%), the overall negative and positive predictive values of the RAD assay were 95.0% (95% CI, 91.9-97.0) and 100%, respectively. In turn, the diagnostic accuracy was 95.6% (95% CI, 93.0-97.5). Seven out of the 10 specimens yielding discordant results (RT-PCR+/RAD-) were run in a multiplexed PCR assay targeting common respiratory viruses.

Interestingly, two of the seven specimens tested positive for Rhinovirus/Enterovirus.

Median SARS-CoV-2 RNA load was significantly higher (p < .001) in NP specimens returning positive results by both tests (median C T , 17.4, equivalent to 8.3 log 10 copies/ml; IQR, C T , 13.7-20.2 and 9.4-7.4 log 10 copies/ml) than in RT-PCR-positive, RAD-negative specimens (median C T , 29.3, equivalent to 4.5 log 10 copies/ml; IQR, C T 24.4-30.9 and 6.1-4.0 log 10 copies/ml). As shown in Table 2 , the sensitivity of the RAD assay was inversely related to the RT-PCR C T (directly related to the SARS.CoV-2 RNA load). ROC analyses identified a RT-PCR C T value of 21.8 (7.0 log 10 copies/ml) as the best discriminator between RAD positive and negative specimens (sensitivity, 100%; specificity, 100%).

Among patients suspected of having COVID-19, those testing RT-PCR positive were older, had close contact with a COVID-19 case, and were more likely to display diarrhea, nausea, asthenia, and headache, whereas rhinorrhea was present more frequently in RT-PCR-negative individuals (Table 1) . Four out of the 10 patients testing RT-PCR+/RAD-required hospitalization. As shown in Table S1 , the shorter time lag from symptoms onset and close contact with a COVID-19 case within the previous 2 weeks were more common in COVID-19 patients testing positive by RAD. The latter parameter was found to be an independent risk factor for RAD positivity (odds ratio, 34.5; 95% CI, 10.9-109.5). yielding rather dissimilar results in terms of sensitivity. 5, 6 In the study by Villaverde at al. 5 the reported overall sensitivity of the Panbio assay was 45%, whereas in that of González-Donapetry at al. 6 it was 77%, which approaches that found in the current study. Neither of the above studies provided the range of RT-PCR C T or the estimated SARS-CoV-2 RNA loads in NP specimens. Interestingly, both studies differed in the timing of specimen collection since the onset of symptoms: ≤5 days in the former study and ≤3 days in the latter, which may explain the discrepancy, provided that SARS-CoV-2 RNA peak load is reached within 48 h after symptoms onset. 7 In this context, the data presented herein, as well as data previously published from our group in a rather small group of children 4 indicated that the likelihood of having a positive RAD assay was significantly higher when NP specimens were collected within that timeframe.

The sensitivity of the Panbio RAD assay reported here and in the above-mentioned studies in children 5, 6 with COVID-19 is notably lower than that reported for adults sampled within a comparable time window (>80% in most studies). 4 Such difference is unlikely to be related to dissimilarities across age groups in terms of SARS-CoV-2 RNA peak load achieved early after COVID-19 presentation. 7 On the other hand, the Panbio RAD assay was found to display an exquisite specificity (100%) and notable prevalence-adjusted NPV and PPV, in line with previous reports. 5, 6 As could be anticipated, patients referring a close contact with a 

of testing for SARS-CoV-2 (COVID-19)

SARS-CoV-2 diagnostic pipeline. Finddx.org. 2021

Real-world clinical performance of commercial SARS-CoV-2 rapid antigen tests in suspected COVID-19: a systematic meta-analysis of available data as per

Field evaluation of a rapid antigen test (Panbio COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres

Diagnostic accuracy of the Panbio SARS-CoV-2 antigen rapid test compared with RT-PCR testing of nasopharyngeal samples in the pediatric population

Think of the children: evaluation of SARS-CoV-2 rapid antigen test in pediatric population

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in the upper respiratory tract of children and adults with early acute coronavirus disease 2019 (COVID-19)

An analysis of SARS-CoV-2 viral load by patient age. medRxiv

Age-related differences in nasopharyngeal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) levels in patients with mild to moderate coronavirus disease 2019 (COVID-19)

Upper respiratory tract SARS-CoV-2 RNA loads in symptomatic and asymptomatic children and adults. medRxiv

Advice on the use of point-of-care immunodiagnostic tests for

Culture-based virus isolation to evaluate potential infectivity of clinical specimens tested for COVID-19

Evaluation of a rapid antigen detection test (Panbio™ COVID-19 Ag Rapid Test Device) as a point-of-care diagnostic tool for COVID-19 in a pediatric emergency department

We thank all personnel working at the Pediatric Department and the